Product Highlight - Nustendi

Add On to Take Back Control: A first-in-class oral, once-daily fixed-dose combination for additional LDL-C lowering¹

• NUSTENDI^® delivered a significant 38% reduction in LDL-C^†2
• Well tolerated in clinical studies and limited musculoskeletal side effect¹
• Can be taken with or without food¹

†vs placebo on top of maximally tolerated statins.²

References:
1. NUSTENDI^®. HK Prescribing Information Apr 2023.
2. Ballantyne CM et al. Eur J Prev Cardiol. 2020; 27(6): 593-603.

HK-DAI-NN-2307007; Date of Approval: Jul 2023